IRIS Accounts Production v23.1.0.753 05081640 director 1.6.22 31.5.23 31.5.23 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pure050816402022-05-31050816402023-05-31050816402022-06-012023-05-31050816402021-05-31050816402021-06-012022-05-31050816402022-05-3105081640ns15:EnglandWales2022-06-012023-05-3105081640ns14:PoundSterling2022-06-012023-05-3105081640ns10:Director12022-06-012023-05-3105081640ns10:PrivateLimitedCompanyLtd2022-06-012023-05-3105081640ns10:SmallEntities2022-06-012023-05-3105081640ns10:AuditExemptWithAccountantsReport2022-06-012023-05-3105081640ns10:SmallCompaniesRegimeForDirectorsReport2022-06-012023-05-3105081640ns10:SmallCompaniesRegimeForAccounts2022-06-012023-05-3105081640ns10:FullAccounts2022-06-012023-05-3105081640ns10:CompanySecretary12022-06-012023-05-3105081640ns10:RegisteredOffice2022-06-012023-05-3105081640ns5:CurrentFinancialInstruments2023-05-3105081640ns5:CurrentFinancialInstruments2022-05-3105081640ns5:ShareCapital2023-05-3105081640ns5:ShareCapital2022-05-3105081640ns5:FurtherSpecificReserve3ComponentTotalEquity2023-05-3105081640ns5:FurtherSpecificReserve3ComponentTotalEquity2022-05-3105081640ns5:RetainedEarningsAccumulatedLosses2023-05-3105081640ns5:RetainedEarningsAccumulatedLosses2022-05-3105081640ns5:FurnitureFittings2022-06-012023-05-3105081640ns5:ComputerEquipment2022-06-012023-05-3105081640ns5:PlantMachinery2022-05-3105081640ns5:PlantMachinery2022-06-012023-05-3105081640ns5:PlantMachinery2023-05-3105081640ns5:PlantMachinery2022-05-3105081640ns5:AdditionsToInvestments2023-05-3105081640ns5:RevaluationsIncreaseDecreaseInInvestments2023-05-3105081640ns5:CostValuation2023-05-3105081640ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-05-3105081640ns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-05-31
REGISTERED NUMBER: 05081640 (England and Wales)















BARTON ONCOLOGY LIMITED

UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MAY 2023






BARTON ONCOLOGY LIMITED (REGISTERED NUMBER: 05081640)

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2023










Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4

Chartered Accountants' Report 7

BARTON ONCOLOGY LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 31 MAY 2023







DIRECTOR: Dr C M Barton





SECRETARY: Kerry Secretarial Services Limited





REGISTERED OFFICE: C/O Cox Costello & Horne
Batchworth Lock House
99 Church Street
Rickmansworth
WD3 1JJ





REGISTERED NUMBER: 05081640 (England and Wales)





ACCOUNTANTS: Cox Costello & Horne
Chartered Accountants and Tax Advisors
Batchworth Lock House
99 Church Street, Rickmansworth
WD3 1JJ

BARTON ONCOLOGY LIMITED (REGISTERED NUMBER: 05081640)

BALANCE SHEET
31 MAY 2023

31.5.23 31.5.22
Notes £ £ £ £
FIXED ASSETS
Tangible assets 4 1,421 2,444
Investments 5 211,772 -
213,193 2,444

CURRENT ASSETS
Debtors 6 9,151 11,873
Cash at bank 287,291 483,267
296,442 495,140
CREDITORS
Amounts falling due within one year 7 49,599 58,190
NET CURRENT ASSETS 246,843 436,950
TOTAL ASSETS LESS CURRENT
LIABILITIES

460,036

439,394

PROVISIONS FOR LIABILITIES 2,623 464
NET ASSETS 457,413 438,930

CAPITAL AND RESERVES
Called up share capital 186 186
Fair value reserve 9,432 -
Retained earnings 447,795 438,744
SHAREHOLDERS' FUNDS 457,413 438,930

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 May 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 May 2023 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

BARTON ONCOLOGY LIMITED (REGISTERED NUMBER: 05081640)

BALANCE SHEET - continued
31 MAY 2023


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Profit and Loss account has not been delivered.

The financial statements were approved by the director and authorised for issue on 13 November 2023 and were signed by:





Dr C M Barton - Director


BARTON ONCOLOGY LIMITED (REGISTERED NUMBER: 05081640)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2023


1. STATUTORY INFORMATION

Barton Oncology Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention as modified by the revaluation of certain assets.

Going concern basis
After making enquiries, the director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future; taken to be 12 months from signing the financial statements. No material uncertainties that cast significant doubt about the ability of the company to continue as a going concern have been identified by the director. The company therefore continues to adopt the going concern basis in preparing its financial statements.

Turnover
Turnover comprises the rendering of services in the ordinary course of the company's activity. Turnover is presented net of value-added tax. The company recognises turnover when the amount of revenue and related costs can be reliably measured, it is probable that the collectability of the related receivables is reasonably assured. Turnover is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

The following criteria must also be met before revenue is recognised:
Rendering of services
Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
- the amount of revenue can be measured reliably;
- it is probable that the company will receive the consideration due under the contract;
- the stage of completion of the contract at the end of the reporting period can be measured reliably; and
- the costs incurred and the costs to complete the contract can be measured reliably.

Interest income
Interest income is recognised in profit or loss using the effective interest method.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Fixtures and fittings - 25% on cost
Computer equipment - 25% on cost

All assets are initially recognised at cost and subsequently carried at cost less accumulated depreciation. The cost of an asset initially recognised includes its purchase price and any cost that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

BARTON ONCOLOGY LIMITED (REGISTERED NUMBER: 05081640)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MAY 2023


2. ACCOUNTING POLICIES - continued

Financial instruments
a) Debtors
Basic financial assets, including trade and other debtors, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Such assets are subsequently carried at amortised cost using the effective interest method, less any impairment.

b) Creditors
Basic financial liabilities, including trade and other creditors, loans from third parties and loans from related parties, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Such instruments are subsequently carried at amortised cost using the effective interest method, less any impairment.

c) Cash at bank
Cash and bank balances are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Such assets are subsequently carried at amortised cost using the effective interest method, less any impairment. Cash and bank balances are represented by cash in hand, deposits held at call with financial institutions, and other short-term highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

Investments
Investments in non-convertible preference shares and non-puttable ordinary or preference shares (where shares are publicly traded or their fair value is reliably measurable) are measured at fair value through profit or loss. Where fair value cannot be measured reliably, investments are measured at cost less impairment.

Taxation
The tax expense for the year comprises current and deferred tax.

Tax is recognised in profit or loss except that a change attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that:
-the recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
-any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Both current and deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Pension costs
The company makes payments into personal retirement schemes of certain employees. The contributions payable by the company and the staff are deposited in the respective pension schemes within 30 days following the deduction. Once the contributions have been paid, the company as employer, has no further obligations. The company's contributions are charged to the profit and loss account in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 1 (2022 - 3 ) .

BARTON ONCOLOGY LIMITED (REGISTERED NUMBER: 05081640)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MAY 2023


4. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£
COST
At 1 June 2022 10,216
Additions 241
At 31 May 2023 10,457
DEPRECIATION
At 1 June 2022 7,772
Charge for year 1,264
At 31 May 2023 9,036
NET BOOK VALUE
At 31 May 2023 1,421
At 31 May 2022 2,444

5. FIXED ASSET INVESTMENTS
Other
investments
£
COST OR VALUATION
Additions 200,000
Revaluations 11,772
At 31 May 2023 211,772
NET BOOK VALUE
At 31 May 2023 211,772


6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.5.23 31.5.22
£ £
Trade debtors 8,262 10,909
Other debtors 889 964
9,151 11,873

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.5.23 31.5.22
£ £
Taxation and social security 33,231 42,135
Other creditors 16,368 16,055
49,599 58,190

8. RELATED PARTY DISCLOSURES

During the reporting year, total dividends of £124,000 (2022 - £124,000) were paid to the director and close family.

CHARTERED ACCOUNTANTS' REPORT TO THE DIRECTOR
ON THE UNAUDITED FINANCIAL STATEMENTS OF
BARTON ONCOLOGY LIMITED


The following reproduces the text of the report prepared for the director in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Director are not required to be filed with the Registrar of Companies.

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Barton Oncology Limited for the year ended 31 May 2023 which comprise the Profit and Loss account, Balance Sheet and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed within the ICAEW's regulations and guidance at http://www.icaew.com/en/membership/regulations-standards-and-guidance.

This report is made solely to the director of Barton Oncology Limited in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of Barton Oncology Limited and state those matters that we have agreed to state to the director of Barton Oncology Limited in this report in accordance with ICAEW Technical Release 07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Barton Oncology Limited and its director for our work or for this report.

It is your duty to ensure that Barton Oncology Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Barton Oncology Limited. You consider that Barton Oncology Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Barton Oncology Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.






Cox Costello & Horne
Chartered Accountants and Tax Advisors
Batchworth Lock House
99 Church Street, Rickmansworth
WD3 1JJ


13 November 2023